GLP-1 dual agonist investigational
Selected indexed studies
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. (JCI Insight, 2020) [PMID:32730231]
- Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. (J Hepatol, 2024) [PMID:38857788]
- Structural determinants of dual incretin receptor agonism by tirzepatide. (Proc Natl Acad Sci U S A, 2022) [PMID:35333651]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. (2024) pubmed
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. (2020) pubmed
- Structural determinants of dual incretin receptor agonism by tirzepatide. (2022) pubmed
- Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial. (2025) pubmed
- Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes. (2022) pubmed
- Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. (2026) pubmed
- Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction. (2024) pubmed
- Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). (2025) pubmed
- Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. (2021) pubmed
- Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs. (2025) pubmed